March 06, 2015 4:12 AM ET

Biotechnology

Company Overview of Regen BioPharma Inc.

Company Overview

Regen Biopharma, Inc., a biotechnology company, focuses on the development of regenerative medical applications in the United States. It intends to provide various products, including HemaXellerate I, a cellular therapy designed to heal damaged bone marrow; HemaXellerate II, a donor endothelial cell based therapeutic product; and dCellVax, a gene silenced dendritic cell immunotherapy for the treatment of breast cancer. The company was founded in 2012 and is based in La Mesa, California. Regen Biopharma, Inc. is a subsidiary of Bio-Matrix Scientific Group, Inc.

4700 Spring Street

Suite 304

La Mesa, CA 91942

United States

Founded in 2012

3 Employees

Phone:

619-702-1404

Fax:

619-330-2328

Key Executives for Regen BioPharma Inc.

Chairman, Chief Executive Officer, President, Principal Accounting Officer, Chief Executive Officer of Bio-Matrix Scientific Group, Treasurer, Secretary, Chairman of Bio-Matrix Scientific Group and Director of Bio-Matrix Scientific Group
Age: 53
Total Annual Compensation: $300.0K
Chief Scientific Officer, Director of Research and Director
Age: 64
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2014.

Regen BioPharma Inc. Key Developments

Regen BioPharma Inc. Declares Dividend on Common Shares, Payable on or About March 20, 2015

On February 18, 2015 the Board of Directors of Regen BioPharma Inc. declared a dividend to common shareholders of record as of March 10, 2015 to be paid to common shareholders on or about March 20, 2015.

Regen Biopharma, Inc. Appoints Todd S. Caven as Chief Financial Officer

On February 11, 2015 the board of directors of Regen Biopharma Inc. appointed Mr. Todd S. Caven, to the position of Chief Financial Officer of Regen. Mr. Caven currently serves as Managing Member of both Rock Ridge Enterprises LLC and Saguaro Capital Partner LLC, where he is solely responsible for making investment decisions on behalf of each company. Prior to that Mr. Caven was the founder and served as Chief Financial Officer of Obstetric Solutions and Interventions where his duties included raising capital for the company, as well as maintaining the financial records of the company.

Regen Biopharma Inc. Identifies Second Generation Gene Silencing Candidates for Blocking Cancer Stem Cell Gene Target

Regen BioPharma Inc. announced the discovery and demonstration of in vitro efficacy of a second generation of gene silencing drug candidates with specificity to the cancer stem cell gene NR2F6. The Company has rights to an invention covered by a non-provisional patent application disclosing compositions of matter, protocols and methods of use of treatment for cancer and other diseases of aberrant cellular proliferation. The patent covers the use of its proprietary novel candidates administered as short interfering nucleic acid (siNA) antisense, short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA). Proof-of-concept studies originally identifying NR2F6 as a target for cancer stem cells were performed by Dr. Christine Ichim, senior research consultant with Regen Biopharma, along with scientists at the University of Toronto. These studies showed that silencing of the NR2F6 gene in leukemia cells led to the cells losing their leukemic characteristics. Cancer stem cells, also known as the cancer initiating cells, are the cells in a cancer that are tumorigenic, meaning they have the ability to cause formation of new tumors when implanted in animals. Blocking their ability to self-renew by silencing NR2F6 transforms cancer cells in to a non-tumorigenic state by guiding cells toward a process called differentiation and cellular maturation.

Similar Private Companies By Industry

Company Name Region
Native Traits Corp United States
Protagonist Therapeutics, Inc. United States
NOSTOC Corporation United States
VasoGenix Pharmaceuticals, Inc. United States
Osprey Biomedical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
January 29, 2015
--
Private Placement
January 22, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Regen BioPharma Inc., please visit www.regenbiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.